High Mortality Rates for Redo Surgery After TAVR

Courtesy of Dr. Carlos Fava.

Since the beginnings of transcatheter aortic valve replacement (TAVR) back in 2002, this strategy has gained considerable ground, encompassing not only inoperable or high-risk patients but also those at medium and low risk. Additionally, it came to include patients with failed bioprostheses.

Incidencia, características y tratamiento de la trombosis valvular post TAVI

However, there is little information on patients who require valve surgery after TAVR (something that is extremely rare).

Researchers analyzed 123 patients from the Society of Thoracic Surgeons (STS) database who required surgical aortic valve replacement after TAVR. Procedures had been conducted between 2011 and 2015.

Mean patient age was 84 years old, and 38% of subjects were female.

Patients were classified according to their STS Predicted Risk of Mortality score. In total, 17% of subjects had an STS score <4%; 24% had a score between 4% and 8%, and the remaining 59% of subjects had a score >8%.

The most common reason for surgery was paravalvular leak, followed by structural prosthetic deterioration, device sizing/position issues, and endocarditis.


Read also: SURTAVI Follow-Up Completed with Good News.


The median time between TAVR and redo surgery was 2.5 months (0.7-13).

Surgical mortality at 30 days was 17.1%. The mortality rate for low-risk patients was 14%; for medium-risk patients, 10%, and for high-risk patients, 21%.

Mortality was higher for patients with endocarditis (25%) and with leak or device sizing/position issues (24%), compared with patients with structural prosthetic deterioration (15%).

Conclusion

Surgery after TAVR failure, which is rare, is associated with a worse-than-expected prognosis compared with similar patients initially undergoing surgery. Technology development is needed to reduce the incidence of early TAVR failure and to define optimal treatment in case of failed TAVR.

Courtesy of Dr. Carlos Fava.

Original title: Reoperation After Transcatheter Aortic Valve Replacement An Analysis of the Society of Thoracic Surgeons Database.

Reference: Oliver K. Jawitz, et al. J Am Coll Cardiol Intv 2020;13:1515-1525.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...